In 2Q17, ABT reported EPS (earnings per share) of $0.62, compared with the analysts’ estimates of 0.61 per share. ABT stock gained ~4% after the announcement on July 20, 2017.
According to the Wall Street analysts’ estimates, the 3Q17 EPS estimate for Abbott Laboratories is $0.65. Abbott Laboratories has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
According to the Wall Street analysts’ projections, Abbott Laboratories is expected to report a gross profit margin of 59.6% of total sales. In 2Q17, the gross profit margin of the company came in at ~59.8% of total sales.
ABT’s adjusted research and development investment is expected to be ~7.5% of sales in 3Q17. However, its adjusted SG&A (selling, general, and administrative) expenditure is expected to be 29% of total sales, compared with its SG&A expenses of 30.1% of sales reported in 2Q17.
Abbott’s major competitors Becton, Dickinson (BDX), Thermo Fisher Scientific (TMO), and Medtronic (MDT) are expected to register YoY (year-over-year) EPS growth of 11.9%, 10.8%, and -14.4%%, respectively.
In the next and final part of this series, we’ll take a look at Abbott’s 3Q17 sales outlook by business segment.